Recent medical management of glioblastoma.
This chapter contains an overview of standard of care and experimental chemotherapy treatments for glioblastoma multiforme (GBM). We discuss the role of alkylating agents, focusing primarily on temozolomide (TMZ) which, in combination with radiation therapy, is part of the standard of care treatment for newly diagnosed GBM. TMZ has proven both well tolerated and effective in prolonging patient survival, but tumor recurrence remains the rule. We review the development and use of molecularly targeted agents, low molecular weight kinase inhibitors and monoclonal antibodies that interrupt the signaling pathways exploited by tumors to grow, migrate and avoid apoptosis.
Department of Neurological Surgery, University of California, San Francisco, CA, USA.
Derek R
DR
Johnson
Susan M
SM
Chang
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D000077204:Temozolomide
D000911:Antibodies, Monoclonal; D047428:Protein Kinase Inhibitors; D003606:Dacarbazine; D000077204:Temozolomide